Ultragenyx Pharmaceutical Inc.

Contributing Author

Recent Articles by Ultragenyx Pharmaceutical Inc.

Sep-30	Ultragenyx Appoints Eric Olson as Chief Business Officer and Executive Vice President RARE GlobeNewswire
Sep-19	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) RARE GlobeNewswire
Sep-08	Ultragenyx Announces Positive Longer-term Data from Phase 3 Study of DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa) RARE GlobeNewswire
Aug-29	Ultragenyx to Participate at Investor Conferences in September RARE GlobeNewswire
Aug-21	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) RARE GlobeNewswire
Aug-18	Ultragenyx Initiates Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa) RARE GlobeNewswire
Aug-05	Ultragenyx Reports Second Quarter 2025 Financial Results and Corporate Update RARE GlobeNewswire
Jul-31	Ultragenyx Completes Enrollment of Phase 3 Aspire Study Evaluating GTX-102 for the Treatment of Angelman Syndrome RARE GlobeNewswire
Jul-30	Ultragenyx to Host Conference Call for Second Quarter 2025 Financial Results and Corporate Update RARE GlobeNewswire
Jul-18	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) RARE GlobeNewswire
Jul-14	Health Canada Extends the Approval of Evkeeza (evinacumab) to Children as Young as 6-months Old with Homozygous Familial Hypercholesterolemia (HoFH) RARE GlobeNewswire
Jul-11	Ultragenyx Receives Complete Response Letter from FDA for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) RARE GlobeNewswire
Jul-09	Ultragenyx and Mereo BioPharma Announce UX143 Phase 3 Orbit Study for Osteogenesis Imperfecta Progressing to Final Analysis RARE GlobeNewswire
Jun-27	Ultragenyx Receives Breakthrough Therapy Designation for GTX-102 in Angelman Syndrome RARE GlobeNewswire
Jun-20	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) RARE GlobeNewswire
Jun-03	Ultragenyx to Participate at Goldman Sachs 46th Annual Global Healthcare Conference RARE GlobeNewswire
May-20	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) RARE GlobeNewswire
May-14	Ultragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact Report RARE GlobeNewswire
May-07	Ultragenyx to Participate at Bank of America's 2025 Healthcare Conference RARE GlobeNewswire
May-06	Ultragenyx Reports First Quarter 2025 Financial Results and Corporate Update RARE GlobeNewswire

Ultragenyx Pharmaceutical Inc.

Recent Articles by Ultragenyx Pharmaceutical Inc.

Upgrade your FINVIZ experience